



· SIXTH EDITION ·

---

HAMILTON & HARDY'S  
**INDUSTRIAL  
TOXICOLOGY**

---

*Edited by*

**RAYMOND D. HARBISON**  
MARIE M. BOURGEOIS · GIFFE T. JOHNSON



**WILEY**



**HAMILTON & HARDY'S  
INDUSTRIAL TOXICOLOGY**



# **HAMILTON & HARDY'S INDUSTRIAL TOXICOLOGY**

---

Sixth Edition

Edited by

**RAYMOND D. HARBISON, MARIE M. BOURGEOIS, AND GIFFE T. JOHNSON**

**WILEY**

Copyright © 2015 by John Wiley & Sons, Inc. All rights reserved

Published by John Wiley & Sons, Inc., Hoboken, New Jersey  
Published simultaneously in Canada

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at [www.wiley.com](http://www.wiley.com).

***Library of Congress Cataloging-in-Publication Data***

Hamilton & Hardy's industrial toxicology. – Sixth edition / editors,  
Raymond D. Harbison, Marie M. Bourgeois, and Giffe T. Johnson.  
p. ; cm.

Hamilton and Hardy's industrial toxicology

Industrial toxicology

Includes bibliographical references and index.

ISBN 978-0-470-92973-5 (hardback)

I. Harbison, Raymond D., editor. II. Bourgeois, Marie M., editor. III. Johnson, Giffe T., editor. IV. Title: Hamilton and Hardy's industrial toxicology. V. Title: Industrial toxicology.

[DNLM: 1. Hazardous Substances—toxicity. 2. Occupational Exposure. 3. Occupational Health. 4. Risk Assessment. WA 465]

RA1229

615.9'02—dc23

2014037175

Printed in the United States of America

10 9 8 7 6 5 4 3 2 1

# CONTENTS

<b>CONTRIBUTORS</b>	<b>xiii</b>
<b>ABBREVIATIONS</b>	<b>xvii</b>
<b>THE HERITAGE OF ALICE HAMILTON MD AND HARRIET HARDY MD</b>	<b>xix</b>
<b>IN MEMORY</b>	<b>xxi</b>
<b>PREFACE</b>	<b>xxiii</b>
<b>SECTION I INTRODUCTION</b>	<b>1</b>
<i>Section Editor: Raymond D. Harbison</i>	
<b>1 The Modern Approach to the Diagnosis of Occupational Disease</b>	<b>3</b>
<i>Raymond D. Harbison and Jeffrey H. Mandel</i>	
<b>2 Controls of Occupational Diseases</b>	<b>13</b>
<i>Daniel A. Newfang, Giffie T. Johnson, and Raymond D. Harbison</i>	
<b>SECTION II METALS AND METALLOIDS</b>	<b>19</b>
<i>Section Editor: Richard V. Lee</i>	
<b>3 Introduction</b>	<b>21</b>
<i>Richard V. Lee</i>	
<b>4 Alkali Compounds</b>	<b>25</b>
<i>Steve Morris and Ann Lurati</i>	
<b>5 Aluminum</b>	<b>33</b>
<i>Giffie T. Johnson</i>	
<b>6 Antimony</b>	<b>39</b>
<i>Marie M. Bourgeois</i>	

<b>7 Arsenic</b>	<b>45</b>
<i>Janice S. Lee and Santhini Ramasamy</i>	
<b>8 Barium</b>	<b>57</b>
<i>Marie M. Bourgeois</i>	
<b>9 Beryllium</b>	<b>63</b>
<i>Alison J. Abritis and Raymond D. Harbison</i>	
<b>10 Bismuth and Related Compounds</b>	<b>73</b>
<i>Paul Jonmaire</i>	
<b>11 Boron</b>	<b>79</b>
<i>Giffe T. Johnson</i>	
<b>12 Cadmium</b>	<b>85</b>
<i>Frank D. Stephen</i>	
<b>13 Chromium</b>	<b>95</b>
<i>Kathleen Macmahon</i>	
<b>14 Cobalt</b>	<b>101</b>
<i>Davinderjit Singh and Raymond D. Harbison</i>	
<b>15 Copper</b>	<b>109</b>
<i>Marie M. Bourgeois</i>	
<b>16 Gallium and Indium</b>	<b>115</b>
<i>Jayme P. Coyle and Raymond D. Harbison</i>	
<b>17 Germanium</b>	<b>119</b>
<i>Marek Banasik</i>	
<b>18 Gold</b>	<b>123</b>
<i>Marek Banasik</i>	
<b>19 Iron</b>	<b>127</b>
<i>Steve Morris and Jayme P. Coyle</i>	
<b>20 Lead</b>	<b>131</b>
<i>Frank D. Stephen</i>	
<b>21 Lithium</b>	<b>141</b>
<i>Ushang Desai</i>	
<b>22 Manganese</b>	<b>149</b>
<i>Alex Lebeau</i>	
<b>23 Mercury</b>	<b>157</b>
<i>Frank D. Stephen</i>	
<b>24 Molybdenum</b>	<b>167</b>
<i>Paul Jonmaire</i>	
<b>25 Nickel</b>	<b>173</b>
<i>Robyn L. Prueitt and Julie E. Goodman</i>	
<b>26 Tantalum and Niobium</b>	<b>183</b>
<i>Jayme P. Coyle and Raymond D. Harbison</i>	
<b>27 Platinum Group Elements: Palladium, Iridium, Osmium, Rhodium, and Ruthenium</b>	<b>187</b>
<i>Alex Lebeau</i>	



<b>28</b>	<b>Platinum</b>	<b>193</b>
	<i>Alex Lebeau</i>	
<b>29</b>	<b>Rare Earth Metals</b>	<b>199</b>
	<i>Raymond D. Harbison and David R. Johnson</i>	
<b>30</b>	<b>Selenium and its Compounds</b>	<b>205</b>
	<i>Anna M. Fan and Marco Vinceti</i>	
<b>31</b>	<b>Silver</b>	<b>229</b>
	<i>Giffé T. Johnson</i>	
<b>32</b>	<b>Tellurium</b>	<b>233</b>
	<i>Marek Banasik</i>	
<b>33</b>	<b>Thallium</b>	<b>239</b>
	<i>Nikolay M. Filipov</i>	
<b>34</b>	<b>Tin</b>	<b>247</b>
	<i>Raymond D. Harbison and David R. Johnson</i>	
<b>35</b>	<b>Titanium</b>	<b>253</b>
	<i>Ushang Desai and Raymond D. Harbison</i>	
<b>36</b>	<b>Tungsten</b>	<b>257</b>
	<i>Kambria K. Haire and Raymond D. Harbison</i>	
<b>37</b>	<b>Vanadium</b>	<b>261</b>
	<i>James C. Ball and Maureen R. Gwinn</i>	
<b>38</b>	<b>Zinc</b>	<b>277</b>
	<i>Giffé T. Johnson</i>	
<b>39</b>	<b>Hafnium and Zirconium</b>	<b>283</b>
	<i>Kambria K. Haire, Jayme P. Coyle, and Raymond D. Harbison</i>	
<b>40</b>	<b>Metal Fume Fever and Metal-Related Lung Disease</b>	<b>289</b>
	<i>Thomas Truncale</i>	
<b>SECTION III CHEMICAL COMPOUNDS I</b>		<b>301</b>
	<i>Section Editor: Raymond D. Harbison</i>	
<b>41</b>	<b>Introduction</b>	<b>303</b>
	<i>Raymond D. Harbison</i>	
<b>42</b>	<b>Carbon Dioxide</b>	<b>305</b>
	<i>Debra J. Price</i>	
<b>43</b>	<b>Carbon Monoxide</b>	<b>309</b>
	<i>Erin L. Pulster and James V. Hillman</i>	
<b>44</b>	<b>Carbon Disulfide</b>	<b>317</b>
	<i>Debra J. Price</i>	
<b>45</b>	<b>Hydrogen Sulfide</b>	<b>325</b>
	<i>Stephen C. Harbison and Jacob R. Bourgeois</i>	
<b>46</b>	<b>Cyanide</b>	<b>331</b>
	<i>Erin L. Pulster and James V. Hillman</i>	

<b>47 Halogens</b>	<b>341</b>
<i>Joseph A. Puccio</i>	
<b>48 Phosgene</b>	<b>357</b>
<i>Benjamin Wong, Michael W. Perkins, and Alfred M. Sciuto</i>	
<b>49 Nitrogen Compounds</b>	<b>363</b>
<i>Kathleen T. Jenkins</i>	
<b>50 Oxygen and Ozone</b>	<b>371</b>
<i>Robert A. Klocke</i>	
<b>51 Phosphorus Compounds</b>	<b>383</b>
<i>M. Rony Francois and Frank Stephen</i>	
<b>52 Sulfur Compounds</b>	<b>391</b>
<i>Frank Stephen and M. Rony Francois</i>	
<b>SECTION IV ORGANIC COMPOUNDS</b>	<b>401</b>
<i>Section Editor: Raymond D. Harbison</i>	
<b>53 Aliphatic Hydrocarbons</b>	<b>403</b>
<i>Mayowa Amosu, Nicole Nation, and Mary Alice Smith</i>	
<b>54 Alcohols and Glycols</b>	<b>419</b>
<i>Kelly W. Hall</i>	
<b>55 Aldehydes and Ketones</b>	<b>445</b>
<i>Jason S. Garcia and Raymond D. Harbison</i>	
<b>56 Ethers and Epoxides</b>	<b>491</b>
<i>Erin L. Pulster, Jacob R. Bourgeois, and Raymond D. Harbison</i>	
<b>57 Esters</b>	<b>505</b>
<i>Raymond D. Harbison and C. Clifford Conaway</i>	
<b>58 Chlorinated Hydrocarbons</b>	<b>541</b>
<i>Michael H. Lumpkin</i>	
<b>59 Other Halogenated Hydrocarbons</b>	<b>567</b>
<i>Michael H. Lumpkin</i>	
<b>60 Aromatic Hydrocarbons</b>	<b>581</b>
<i>Raymond D. Harbison, Amora Mayo-Perez, David R. Johnson, and Marie M. Bourgeois</i>	
<b>61 Amino and Nitro Compounds</b>	<b>615</b>
<i>David Y. Lai and Yin-Tak Woo</i>	
<b>62 Methyl Tert-Butyl Ether (MTBE)</b>	<b>643</b>
<i>Janice S. Lee and Robyn Blain</i>	
<b>63 Ethyl Tertiary Butyl Ether (ETBE)</b>	<b>651</b>
<i>Keith D. Salazar</i>	
<b>64 tert-Butyl Alcohol</b>	<b>657</b>
<i>Janice S. Lee</i>	
<b>65 Naphthalene</b>	<b>663</b>
<i>Lisa A. Bailey, Laura E. Kerper, and Lorenz R. Rhomberg</i>	

<b>66 Gasoline (Petrol, Motor Spirits, Motor Fuel, Natural Gasoline, Benzin, Mogas)</b>	<b>669</b>
<i>Raymond D. Harbison and Daniel A. Newfang</i>	
<b>67 1-Bromopropane</b>	<b>677</b>
<i>Marek Banasik</i>	
<b>68 Diacetyl</b>	<b>683</b>
<i>David J. Hewitt</i>	
<b>69 Perfluoroalkyl Compounds</b>	<b>689</b>
<i>Jason S. Garcia and Raymond D. Harbison</i>	
<b>70 Tetrahydrofuran</b>	<b>719</b>
<i>Ghazi A. Dannan</i>	
<b>71 Perchloroethylene (Tetrachloroethylene)</b>	<b>727</b>
<i>David G. Dodge and Julie E. Goodman</i>	
<b>72 Trichloroethylene</b>	<b>733</b>
<i>David G. Dodge and Julie E. Goodman</i>	
<b>73 Acrylonitrile</b>	<b>741</b>
<i>Jason M. Fritz and April M. Luke</i>	
<b>SECTION V ORGANIC HIGH POLYMERS, MONOMERS, AND POLYMER ADDITIVES</b>	<b>755</b>
<i>Section Editor: Raymond D. Harbison</i>	
<b>74 Introduction</b>	<b>757</b>
<i>Raymond D. Harbison</i>	
<b>75 Plastics</b>	<b>759</b>
<i>Marek Banasik</i>	
<b>76 Elastomers</b>	<b>785</b>
<i>Marek Banasik</i>	
<b>77 Synthetic Fibers</b>	<b>791</b>
<i>Marek Banasik</i>	
<b>78 Bisphenol A (4,4'-Isopropylidenediphenol)</b>	<b>795</b>
<i>Julie E. Goodman, Lorenz R. Rhomberg, and Michael K. Peterson</i>	
<b>79 Polystyrene/Styrene</b>	<b>809</b>
<i>Leslie A. Beyer and Julie E. Goodman</i>	
<b>80 Phthalates</b>	<b>815</b>
<i>Robert W. Benson</i>	
<b>81 Decabromodiphenyl Ethane</b>	<b>821</b>
<i>Marek Banasik</i>	
<b>82 Tetrabromobisphenol A</b>	<b>827</b>
<i>David Y. Lai</i>	
<b>83 Tris[2-Chloro-1-(Chloromethyl)Ethyl] Phosphate (TDCPP)</b>	<b>837</b>
<i>Marek Banasik</i>	

<b>84</b>	<b>Tris(2-Chloro-1-Methylethyl) Phosphate (TCPP)</b>	<b>845</b>
	<i>Marek Banasik</i>	
<b>SECTION VI PESTICIDES</b>		<b>855</b>
	<i>Section Editor: Raymond D. Harbison</i>	
<b>85</b>	<b>Introduction</b>	<b>857</b>
	<i>Raymond D. Harbison</i>	
<b>86</b>	<b>Insecticides</b>	<b>859</b>
	<i>Carol S. Wood</i>	
<b>87</b>	<b>Herbicides</b>	<b>877</b>
	<i>Giffe T. Johnson</i>	
<b>88</b>	<b>Fungicides</b>	<b>901</b>
	<i>Amora Mayo-Perez and Raymond D. Harbison</i>	
<b>89</b>	<b>Rodenticides</b>	<b>917</b>
	<i>Daniel L. Sudakin</i>	
<b>SECTION VII DUSTS AND FIBERS</b>		<b>927</b>
	<i>Section Editor: Raymond D. Harbison</i>	
<b>90</b>	<b>Introduction</b>	<b>929</b>
	<i>David R. Johnson</i>	
<b>91</b>	<b>Benign Dusts (Nuisance Dusts)</b>	<b>931</b>
	<i>Humairat H. Rahman and Raymond D. Harbison</i>	
<b>92</b>	<b>Fibrogenic Dusts</b>	<b>935</b>
	<i>Charles Barton</i>	
<b>93</b>	<b>Mixed Dusts</b>	<b>949</b>
	<i>Charles Barton</i>	
<b>94</b>	<b>Synthetic Vitreous Fibers</b>	<b>959</b>
	<i>Thomas Truncale and Yehia Y. Hammad</i>	
<b>95</b>	<b>Organic Dusts</b>	<b>969</b>
	<i>David R. Johnson</i>	
<b>96</b>	<b>Naturally Occurring Mineral Fibers</b>	<b>997</b>
	<i>Ali K. Hamade, Christopher M. Long, and Peter A. Valberg</i>	
<b>97</b>	<b>Nanoparticles</b>	<b>1025</b>
	<i>Daniel A. Newfang, Giffe T. Johnson, and Raymond D. Harbison</i>	
<b>SECTION VIII PHYSICAL AGENTS</b>		<b>1029</b>
	<i>Section Editor: Marie Bourgeois</i>	
<b>98</b>	<b>Radio-Frequency Radiation</b>	<b>1031</b>
	<i>R. Timothy Hitchcock</i>	
<b>99</b>	<b>Optical Radiation: Ultraviolet, Visible Light, Infrared, and Lasers</b>	<b>1045</b>
	<i>Joseph M. Greco</i>	

<b>100 Ionizing Radiation</b>	<b>1055</b>
<i>Thomas A. Lewandowski, Juhi K. Chandalia, and Peter A. Valberg</i>	
<b>101 Electromagnetic Waves (EMF and RF) and Health Effects</b>	<b>1069</b>
<i>Peter A. Valberg</i>	
<b>102 Traumatogens Associated with Carpal Tunnel Syndrome</b>	<b>1087</b>
<i>Joan M. Watkins</i>	
<b>103 Vibration</b>	<b>1099</b>
<i>Donald E. Wasserman</i>	
<b>104 Occupational Noise</b>	<b>1115</b>
<i>David L. Dahlstrom</i>	
<b>105 Heat Stress Illness</b>	<b>1123</b>
<i>Marie M. Bourgeois and David R. Johnson</i>	
<b>SECTION IX SPECIAL TOPICS</b>	<b>1129</b>
<i>Section Editor: Raymond D. Harbison</i>	
<b>106 Mode of Action/Human Relevance Framework</b>	<b>1131</b>
<i>M.E. (Bette) Meek</i>	
<b>107 Carcinogenesis</b>	<b>1135</b>
<i>Carlos A. Muro-Cacho</i>	
<b>108 Genotoxicity Testing Strategies, Guidelines, and Methods</b>	<b>1173</b>
<i>Ching-hung Hsu and Qingli Wang</i>	
<b>109 Human Relevance of Rodent Leydig Cell Tumors</b>	<b>1189</b>
<i>Thomas J. Steinbach, Robert. R. Maronpot, and Jerry F. Hardisty</i>	
<b>110 Reproductive Toxicology</b>	<b>1197</b>
<i>Judith W. Henck</i>	
<b>111 Developmental Toxicology</b>	<b>1229</b>
<i>Thomas A. Lewandowski</i>	
<b>112 Ototoxicity</b>	<b>1241</b>
<i>Matthew Mifsud and K. Paul Boyev</i>	
<b>113 Dermal and Ocular Toxicity</b>	<b>1247</b>
<i>Jayne P. Coyle, Alison J. Abritis, Amora Mayo-Perez, Marie M. Bourgeois, and Raymond D. Harbison</i>	
<b>114 Reactive Airways Dysfunction Syndrome (RADS)</b>	<b>1259</b>
<i>David J. Hewitt</i>	
<b>115 Pulmonary Sensitization</b>	<b>1263</b>
<i>David J. Hewitt</i>	
<b>116 “Street” and Prescription Drug Abuse</b>	<b>1267</b>
<i>Sharon S. Kelley, James Godin, and John Christie</i>	
<b>117 Mycotoxins</b>	<b>1283</b>
<i>Clara Y. Chan and Bruce J. Kelman</i>	

<b>118 Phosphine</b>	<b>1295</b>
<i>Michael W. Perkins, Benjamin Wong, Dorian Olivera, and Alfred Sciuto</i>	
<b>119 Diesel Exhaust</b>	<b>1301</b>
<i>J. Michael Berg, Phillip T. Goad, and Thomas W. Hesterberg</i>	
<b>120 Spaceflight Operations</b>	<b>1311</b>
<i>Michael A. Cardinale, Philip J. Scarpa, James R. Taffer, and Daniel Woodard</i>	
<b>121 Regulatory Toxicology</b>	<b>1321</b>
<i>David M. Polanic and Marek Banasik</i>	
<b>INDEX</b>	<b>1331</b>

# CONTRIBUTORS

**Alison J. Abritis, MPH**, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Mayowa Amosu**, Laboratory Manager, Smith Lab Environmental Health Sciences, University of Georgia, Athens, GA, USA

**Lisa A. Bailey, PhD**, Gradient Corporation, Cambridge, MA, USA

**James C. Ball, PhD**, Research Scientist, Integrated Risk Information System (IRIS), U.S. Environmental Protection Agency, Washington, DC, USA

**Marek Banasik, MD, PhD**, Institute of Public Health and Environmental Protection, Warsaw, Poland

**Charles Barton, PhD, DABT**, Senior Toxicologist & Toxicology Program Manager, Oak Ridge Institute for Science and Education (ORISE), Oak Ridge Associated Universities (ORAU), Oak Ridge, TN, USA

**Robert W. Benson, PhD**, Toxicologist, Office of Partnerships and Regulatory Assistance, U.S. Environmental Protection Agency, Denver, CO, USA

**J. Michael Berg, PhD**, Toxicologist, Center for Toxicology and Environmental Health, LLC, Houston, TX, USA

**Leslie A. Beyer, MS, DABT**, Gradient Corporation, Arlington, MA, USA

**Robyn Blain, MS, PhD**, Technical Specialist, ICF International, Fairfax, VA, USA

**Jacob R. Bourgeois, BS, ChE**, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Marie M. Bourgeois, PhD, MPH**, Research Assistant Professor, Center for Environmental/Occupational Risk Analysis and Management, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**K. Paul Boyev, MD**, Associate Professor, Director, Division of Otolaryngology-Neurotology, Residency Program Director, Department of Otolaryngology-Head and Neck Surgery, College of Medicine, University of South Florida, Tampa, FL, USA

**Michael A. Cardinale, MS, CIH**, Environmental Health Officer John F. Kennedy Space Center National Aeronautics and Space Administration NASA-Kennedy Space Center, FL, USA

**Vincent Castranova, PhD**, National Institute for Occupational Safety and Health, Morgantown, WV, USA

**Clara Y. Chan, MSc, DABT**, Senior Toxicologist, Veritox, Inc., Redmond, WA, USA

**Juhi K. Chandalia**, Data Scientist, Zettics, Concord, MA, USA

**John Christie, RD, CSSD, CSCS**, Performance Nutritionist, Phoenix, AZ, USA

**C. Clifford Conaway, PhD, DABT**, Department of Pharmacology New, York Medical College, Valhalla, NY, USA

**Jayne P. Coyle, MSPH**, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Ghazi A. Dannan, PhD**, Office of Research and Development, National Center for Environmental Assessment,

U.S. Environmental Protection Agency, Washington, DC, USA

**Ushang Desai, MBBS, MPH**, Research Assistant, Center of Environmental & Occupational Risk Analysis, Department of Environmental & Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**David G. Dodge, MS, DABT**, Senior Toxicologist, Gradient, Cambridge, MA, USA

**Anna M. Fan, PhD**, Chief, Pesticide and Environmental Toxicology Branch, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland/Sacramento, CA, USA

**Nikolay M. Filipov, PhD**, Department of Physiology and Pharmacology, College of Veterinary Medicine, University of Georgia, Athens, GA, USA

**M. Rony Francois, MD, MSPH, PhD**, Director for Public Health Services, Supervisory Occupational Medicine Physician, Public Health Emergency Officer, Naval Health Clinic, Corpus Christi, TX, USA

**Jason M. Fritz, PhD**, Toxicologist, Office of Research and Development, National Center for Environmental Assessment/Integrated Risk Information System, U.S. Environmental Protection Agency, Washington, DC, USA

**Jason S. Garcia, MPH, CPH**, College of Public Health, University of South Florida, Tampa, FL, USA

**Phillip T. Goad, PhD**, Toxicologist, Center for Toxicology and Environmental Health, LLC, North Little Rock, AR, USA

**James Godin, DPT, CSCS**, Director of Tactical Performance Rehabilitation, EXOS, Inc., Tampa, FL, USA

**Julie E. Goodman, PhD, DABT**, Gradient Corporation, Cambridge, MA, USA

**Joseph M. Greco, CHP, CLSO, VP**, Imaging Physics, Upstate Medical Physics—A Landauer Medical Physics Partner, Victor, NY, USA

**Maureen R. Gwinn, PhD, DABT**, Associate National Program Director, Community Health, Sustainable and Healthy Communities, National Center for Environmental Assessment, Washington, DC, USA

**Kambria K. Haire, MPH**, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Kelly W. Hall, MPH, PhD**, Associate Director, Toxicology, Global Product Safety and Toxicology, Merck Consumer Care, Memphis, TN, USA

**Ali K. Hamade, PhD, DABT**, Environmental Public Health Program Manager, Alaska Section of Epidemiology, Division of Public Health, Department of Health and Social Services, Anchorage, AK, USA

**Yehia Y. Hammad, DSc**, Professor, College of Public Health University of South Florida, Tampa, FL, USA

**Raymond D. Harbison, PhD, ATS**, Professor, Center for Environmental/Occupational Risk Analysis and Management, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Stephen C. Harbison, PhD, MPH**, Southwestern Energy Company, Conway, AR, USA

**Jerry F. Hardisty, DVM**, Experimental Pathology Laboratories, Inc., Research Triangle Park, NC, USA

**Judith W. Henck, PhD, DABT**, Research Advisor, Non-clinical Safety Assessment, Eli Lilly and Company, Greenfield, Indiana, USA

**Thomas W. Hesterberg, PhD, MBA**, Senior Toxicologist, Center for Toxicology and Environmental Health, LLC, Denver, CO, USA

**David J. Hewitt, MD, MPH, DABT**, Resources for Environmental and Occupational Health (REOH), Missoula, MT, USA

**James V. Hillman, MD, FAAP, FACEP, FACMT**, Clinical Professor of Pediatrics, University of South Florida College of Medicine, Tampa, FL, USA

**R. Timothy Hitchcock, CIH, CLSO**, LightRay Consulting, Inc., Cary, NC, USA

**Ching-Hung Hsu, PhD, DABT**, HEC Pharm Group, China

**Kathleen T. Jenkins, MD, MPH**, Florida Association of Occupational and Environmental Medicine, Tampa, FL, USA

**David R. Johnson, MD, MS, MHA, FACOEM, DABT**, Professor Center for Environmental/Occupational Risk Analysis and Management, Department of Environmental and Occupational Health, University of South Florida College of Public Health, Tampa, FL, USA

**Giffe T. Johnson, PhD, MPH**, Research Assistant Professor, Center for Environmental/Occupational Risk Analysis and Management, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA

**Paul Jonmaire, PhD**, Director, Health & Safety/Toxicology, Ecology and Environment, Inc., Lancaster, NY, USA



- Sharon S. Kelley, MS, PhD**, Chief Executive officer, Associates in Emergency Medical Education, Inc., Tampa, FL, USA
- Bruce J. Kelman, PhD, DABT, FATS**, European Registered Toxicologist, United Kingdom and EUROTOX Registries, University of Edinburgh, Edinburgh, UK
- Laura E. Kerper, PhD**, Gradient Corporation, Cambridge, MA, USA
- Robert A. Klocke, MD**, Emeritus Professor and Chair, Department of Medicine, University at Buffalo, Buffalo, NY, USA
- David Y. Lai, PhD, DABT**, Senior Toxicologist, Risk Assessment Division, Office of Pollution Prevention and Toxics, U.S. Environmental Protection Agency, Washington, DC, USA
- Alex LeBeau, PhD, MPH**, Toxicologist/Environmental Scientist, Conestoga-Rovers & Associates, Inc., Dallas, TX, USA
- Janice S. Lee, MHS, PhD**, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Research Triangle Park, NC, USA
- Richard V. Lee**, Professor, Department of Medicine, School of Medicine, University of Buffalo, The State University of New York, Buffalo, NY, USA
- Thomas A. Lewandowski, PhD, DABT, ERT**, Toxicologist, Gradient Corporation, Seattle, WA, USA
- Haixia Lin**, Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Jefferson, AR, USA
- Christopher M. Long, ScD, DABT**, Principal Scientist, Gradient Corporation, Cambridge, MA, USA
- April M. Luke, MS**, Toxicologist, Office of Research and Development, National Center for Environmental Assessment/Integrated Risk Information System, U.S. Environmental Protection Agency, Washington, DC, USA
- Ann Lurati, ARNP, ACNP-BC, DNP, MPH, COHN-S**, Occupational Health Nurse Practitioner, University of South Florida, Tampa, FL, USA
- Michael H. Lumpkin, PhD, DABT**, Senior Toxicologist, Center for Toxicology and Environmental Health, LLC, Little Rock, AR, USA
- Jeffrey H. Mandel, MD, MPH**, Associate Professor, Division of Environmental Health Sciences, University of Minnesota School of Public Health, Minneapolis, MN, USA
- Kathleen MacMahon, DVM, MS**, Education and Information Division, National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention Cincinnati, OH, USA
- Mugimane G. Manjanatha**, Division of Genetic and Molecular Toxicology, National Center for Toxicological Research, Jefferson, AR, USA
- Robert R. Maronpot, DVM, MS, MPH, DACVP, DABT, FIATP**, Maronpot Consulting, LLC, Raleigh, NC, USA
- M.E. (Bette) Meek**, Institute of Population Health, University of Ottawa, Ottawa, Canada
- Matthew Mifsud, MD**, Department of Otolaryngology-Head and Neck Surgery, University of South Florida, Tampa, FL, USA
- Steven Morris, MD, RN**, Assistant Professor, Basic Sciences, College of Nursing, University of South Florida, Tampa, FL, USA
- Carlos A. Muro-Cacho, MD**, Professor, Pathology and Cell Biology, University of South Florida; Chief, Anatomic Pathology, James A. Haley Veterans' Hospital, Tampa, FL, USA
- Nicole Nation**, University of Georgia, Athens, GA, USA.
- Daniel A. Newfang, MS, CIH, CSP**, Center for Environmental/Occupational Risk Analysis and Management, Department of Environmental and Occupational Health, College of Public Health, University of South Florida, Tampa, FL, USA
- Dorian S. Olivera MS, PhD, CLAD**, Inhalation Toxicology Program Manager, Technology Solutions Group, Life Sciences Division, Alion Science and Technology Corporation, Durham, NC, USA
- Michael K. Peterson, MEM, DABT**, Senior Toxicologist, Gradient Corporation, Cambridge, MA, USA
- Michael W. Perkins, PhD**, Research Physical Scientist, Analytical Toxicology Division, U.S. Army Medical Research, Institute of Chemical Defense, MD, USA
- David M. Polanic, JD**, College of Law, Michigan State University, East Lansing, MI, USA
- Debra J. Price, PhD, MSPH, MEd**, Director of Education, Health Services Advisory Group. Inc., Tampa, FL, USA
- Joseph A. Puccio, MD, FAAP**, Medical Director, Student Health Center, College of Medicine, University of South Florida, Tampa, FL, USA
- Erin L. Pulster, MSMS**, Senior Chemist and Laboratory Manager, Environmental Laboratory of Forensics, Mote Marine Laboratory, Sarasota, FL, USA

**Humairat H. Rahman, MBBS, MPH**, Department of Environmental and Occupational Health, University of South Florida College of Public Health, Tampa, FL, USA

**Santhini Ramasamy, PhD, MPH, DABT**, Senior Toxicologist, Office of Water, Office of Science and Technology, U.S. Environmental Protection Agency, Washington, DC, USA

**Lorenz R. Rhomberg, PhD, ATS**, Gradient Corporation, Cambridge, MA, USA

**Keith D. Salazar, PhD**, National Center for Environmental Assessment, U.S. Environmental Protection Agency, Washington, DC, USA

**Philip J. Scarpa, Jr, MD, MS, FAsMA**, Deputy Chief Medical Officer, John F. Kennedy Space Center, National Aeronautics and Space Administration, NASA-Kennedy Space Center, FL, USA

**Alfred M. Sciuto, PhD**, Fellow, Academy of the Toxicological Society, Research Physiologist, Medical Toxicology Branch, Analytical Toxicology Division, U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA

**Davinderjit Singh MBBS, MPH**, Toxicology and Risk Assessment, Environmental and Occupational Health College of Public Health, University of South Florida, Tampa, FL, USA

**Mary Alice Smith, PhD**, Associate Professor, Environmental Health Science Department, University of Georgia, Athens, GA, USA

**Thomas J. Steinbach, DVM, DACVP, DABT**, Experimental Pathology Laboratories, Inc., Sterling, VA, USA

**Frank D. Stephen, PhD**, Assistant Professor of Biology, Department of Math & Natural Sciences, D'Youville College, Buffalo, New York, USA

**Daniel L. Sudakin, MD, MPH, FACMT, FACOEM**, Associate Professor, Oregon State University, Department

of Environmental and Molecular Toxicology, Corvallis, OR, USA

**James R. Taffer, MSPH, CIH**, Manager, Environmental Health Services, InoMedic Health Applications, Inc. John F. Kennedy Space Center, FL, USA

**Thomas Truncale, DO, MPH**, Associate Professor of Medicine, Program Director, Occupational Medicine Residency, University of South Florida, James A. Haley Veterans' Hospital, Tampa, FL, USA

**Peter A. Valberg, PhD**, Principal, Environmental Health, Gradient Corporation, Cambridge, MA, USA

**Marco Vinceti, MD, PhD**, Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy

**Qingli Wang**, Center for Drug Evaluation, Chinese Food and Drug Administration (CFDA), Beijing, China

**Donald E. Wasserman, MSEE, MBA**, Independent Occupational Vibration Consultant, D.E. Wasserman, Inc., Frederick, MD, USA

**Joan M. Watkins, DO, MPH**, Affiliate Faculty, Occupational and Environmental Medicine Residency, College of Public Health and College of Medicine, University of South Florida, Tampa, FL, USA

**Benjamin Wong, BS PhD**, Research Physical Scientist, MTB, ATD, United States Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, MD, USA

**Carol S. Wood, PhD, DABT**, Oak Ridge National Laboratory, Oak Ridge, TN, USA

**Daniel Woodard, MD**, Aerospace Physician InnoMedic Health Applications, Kennedy Space Center, FL, USA

**Yin-tak Woo, PhD, DABT**, Senior Toxicologist, Risk Assessment Division, Office of Chemical Safety Pollution Prevention, U.S. Environmental Protection Agency Washington, DC, USA

## ABBREVIATIONS

5-HT	5-Hydroxytryptamine	ECG	Electrocardiography
AAS	Anabolic androgenic steroids	EME	Ecgonine methyl ester
ACGIH	American Conference of Governmental Industrial Hygienists	EPA	Environmental Protection Agency
AIHA	American Industrial Hygiene Association	EU	European Union
ARDS	Acute respiratory distress syndrome	FEV <sub>1</sub>	1-Minute forced expiratory volume
ASSE	American Society of Safety Engineers	FVC	Forced vital capacity
ATA	Atmospheres absolute pressure	GABA	Gamma-aminobutyric acid
ATP	Adenosine triphosphate	GBL	Gamma-butyrolactone
ATSDR	Agency for Toxic Substances Disease Registry	GC	Gas chromatography
BEI	Biological exposure indices	GC-MS	Gas chromatography/mass spectrometry
BZE	Benzoyllecgonine	GHB	Gamma-hydroxybutyric acid
CaO	Calcium oxide	GHS	Globally Harmonized System of Classification and Labelling of Chemicals
CASRN	Chemical Abstract Service Registry Number	HCl	Hydrochloric acid
CB	Control banding	HCN	Hydrogen cyanide
CDC	Center for Disease Control and Prevention	HDL <sub>c</sub>	High-density lipoprotein concentration
CH <sub>2</sub> Cl <sub>2</sub>	Dichloromethane	HOCl	Hypochlorous acid
CH <sub>3</sub> CN	Acetonitrile	H <sub>2</sub> S	Hydrogen sulfide
CIH	Certified Industrial Hygienist	HSE	Health Safety Executive
CN <sup>-</sup>	Cyanide anion	IDLH	Immediately Dangerous to Life and Health
CNS	Central nervous system	IHD	Ischemic heart disease
CO	Carbon monoxide	ILO	International Labour Organization
CO <sub>2</sub>	Carbon dioxide	IRIS	Integrated Risk Information System
COHb	Carboxyhemoglobin	LC-MS	Liquid chromatography/mass spectrometry
CONSB	Carbon Monoxide Neuropsychological Screening Battery	LC-MS/MS	Liquid chromatography/tandem mass spectrometry
CS <sub>2</sub>	Carbon disulfide	LDL <sub>c</sub>	Low-density lipoprotein concentration
CSA	Controlled Substances Act	LOD	Limit of detection
CSP	Certified Safety Professional	MAPK	Mitogen-activated protein kinase
CWA	Chemical warfare agent	MGP	Manufactured gas plants
DEA	Drug Enforcement Agency	MMF	Midmaximal flow
DNEL	Derived no effect level	MRLs	Minimal risk levels
DNS	Delayed neuropsychiatric syndrome	MS	Mass spectrometry
DPE	Delayed postanoxic encephalopathy	NaCN	Sodium cyanide

NGOs	Non-governmental organizations	PM <sub>2.5</sub>	Particulate matter
NIOSH	National Institute of Occupational Safety and Health	PtD	Prevention through design
NMMAPS	National Morbidity, Mortality, and Air Pollution Study	RADS	Reactive airways dysfunction syndrome
NRC	Nuclear Regulatory Commission	RBC	Red blood cell
OEB	Occupational exposure band	REL	Recommended exposure limit
OEHS	Occupational and Environmental Health and Safety	ROS	Reactive oxygen species
OEL	Occupational exposure limit	SDS	Safety data sheet
OR	Odds ratio	SEG	Similar exposure group
OSHA	Occupational Safety and Health Administration	SLs	Screening levels
PAH	Polycyclic aromatic hydrocarbon	SMR	Standardized mortality ratio
PEL	Permissible exposure limit	STEL	Short-term exposure limit
PPE	Personal protective equipment	THC	Delta-9-tetrahydrocannabinoid
		TLV	Threshold limit value
		UK	United Kingdom
		U.S.	United States
		WHO	World Health Organization

## THE HERITAGE OF ALICE HAMILTON, M.D. AND HARRIET HARDY, M.D.

It has been over a century since Alice Hamilton graduated medical school, and almost a century since Harvard appointed her as the first female associate professor. It has only been just under three-quarters of a century since the first female full professor at Harvard, Harriet Hardy, was appointed. Few working people entering the fields of occupational and environmental health and hygiene are old enough to appreciate the incredible strides made in these fields to protect workers, families, flora, and fauna. Even fewer still are old enough to understand the personal and professional battles fought by Dr. Hamilton and Dr. Hardy in just trying to attend college, gain employment in their field, and establish the credibility automatically and generously granted to men with lesser education and experience.

Both women had to limit their choices of educational institutions to those designed or willing to accept women. Both had to withstand accusations of emotionalism and “hysteria” as naysayers sought to discredit them. Dr. Hamilton achieved a notable landmark in being appointed the first woman faculty at Harvard, but her position was without several of the privileges enjoyed by the male faculty, and she retired from Harvard still an associate professor. Dr. Hardy was similarly notable in her appointment as full professor at Harvard, but she suffered from several physical ailments that took a severe toll on her. However, it would be truly shortsighted to view their difficulties and successes only in terms of gender issues. They were scientists, first and foremost, and most of the dissension encountered during their professional

lives was primarily due to their challenging the deep-seated socially dismissive attitude toward worker health, the associations between chemicals and illness, and the industries’ unwillingness to incur expenses in attending to employee needs.

Certainly, the dimming of memories signifies positive strides in occupational and environmental health goals and gender equality. However, the historical advances in occupational and environmental health are now so much a part of our way of life that we risk losing the appreciation of the sacrifices, and the successes of the people behind these changes. Neither Dr. Hamilton nor Dr. Hardy proffered theories that were gracefully met with acceptance, regardless of the supporting evidence or the number of potential lives at risk. Their strength of character drove them, which in turn propelled the changes they sought.

*Industrial Toxicology* was first drafted by Dr. Hamilton in 1934. Fifteen years later, she teamed with her colleague Dr. Hardy for the second edition. The subsequent editions maintain their names in the title, not just as courtesy but as a genuine homage to their impressive contributions to the health and welfare of global populations, at times at great expense to their own personal life and health. Perhaps, ultimately, this is the legacy carried forth with these volumes, the reason we need to remember exactly who these women were and what they accomplished—so that we may honor them by our dedication and sacrifice in striving for greater knowledge and safer lives.



## IN MEMORY

During the lengthy process of creating this sixth edition, we lost one of our most integral people when, on May 7, 2013, Dr. Richard Vaile Lee passed away. A brilliant physician and educator, Dick Lee was also a valued friend and colleague.



Dr. Lee began his collegiate experience at Yale, where he received both his B.S. and M.D. and gained membership in the Alpha Omega Alpha Honor Medical Society. His internship and residency concentration was internal medicine. Between his residency years, he also squeezed in 2 years of service at the Fort Peck Indian Reservation in Montana for the U.S. Public Health Service, remaining an additional year to assist a colleague in general practice. Upon his return to Yale, he completed his residency and was awarded a fellowship in infectious diseases. While a fellow, he also acted as Director for the medical clinics and emergency room for the Department of Medicine.

In 1976, Dr. Lee left Yale to assume the positions of Professor and Vice Chairman of the Department of Medicine at the State University of New York at Buffalo (UB), and Chief of Medical Services for the Buffalo Veterans

Administration Medical Center. In 1979, he took over as Head of the Department of Medicine at Buffalo's Children's Hospital. In 1997, he left Children's Hospital to establish a private practice in obstetrics medicine.

Dr. Lee's practice was not confined to a simple driving radius. He practiced "geographic medicine," bringing much-needed medical care and attention to remote locations. He treated tribal cultures in Northern Kenya and Brazil, and he traveled to Thailand, treating refugees from Laos and Cambodia. He developed an acquaintance with the Dalai Lama through his work with Tibetan refugees and was part of the UB board responsible for Dalai Lama's trip to Buffalo in 2006. He developed the UB's Medical Trek Program, sending students to perform medical care in field expeditions across the world.

The range of scholarship was almost as broad as the countries traveled. In addition to his experience in general practice, infectious diseases, and obstetrics, Dr. Lee also served as Medical Director for Ecology and Environment, Inc., in Lancaster. He taught classes at UB in pediatrics, gynecology, and obstetrics in the School of Medicine and Biomedical Sciences as well as various classes in the Department of Social and Preventive Medicine in the School of Public Health and Health Professions, and in the Department of Anthropology in the College of Arts and Sciences. He also served as a consulting physician to both the Buffalo Zoo and the Bronx Zoo.

His marriage in 1961 to Susan Bradley ultimately produced two sons, Benjamin and Matthew. It also unearthed a family secret. When he announced his impending marriage to his family, Dr. Lee learned that his paternal grandfather was Li Yan Phou, one of a select group of Chinese students to attend school in the United States. Because of strong anti-Asian prejudice (at the time there were laws preventing

Chinese and non-Chinese intermarriages in some states), Dr. Lee's parents had opted to hide the Asian heritage. However, Dr. Lee embraced his Chinese heritage, serving as a trustee for the Yale–China Association and participating in a UB delegation to China to renew an academic affiliation with a Beijing university. He also edited and wrote the foreword for the 2004 edition of his grandfather's book, *When I was a Boy in China*, published under the Anglicized name of Yan Phou Lee.

Dr. Lee produced over 70 publications and garnered several awards. In 2002, he was the Laureate Award winner

of the American College of Physicians–American Society of Internal Medicine, and in 2007, he was the winner of the C.G. Barnes Award from International Society of Obstetric Medicine. In the same year, the North American Society of Obstetric Medicine established a lecture in his name for their annual meetings.

So we dedicate this edition to Richard V. Lee, M.D., FACP, FPGS: a scholar, a humanitarian, an educator, a leader, a traveler, a guide, a speaker, a listener, and ultimately an inspiration. By his own words: “a professor.” By our words, a great man.



# PREFACE

The sixth edition of *Hamilton & Hardy's Industrial Toxicology* has been updated and expanded with new chapters on aspects of regulatory toxicology, toxicity testing, physical hazards, high production volume (HPV) chemicals, and workplace drug use. The format has been modified and now includes information on occupational and environmental sources of exposure, mammalian toxicology, industrial hygiene, medical management, and ecotoxicology where appropriate. The book is organized by substance and includes the latest research on industrial toxicants. The goal was to provide a broad range of professionals with an accessible text. We are extremely grateful to our contributors as they provided integral industry, regulatory, and academic perspectives.

The landscape of industrial toxicology has changed considerably since Dr. Alice Hamilton and Dr. Harriet Hardy published the first edition of the text in 1929. It is estimated that there are now more than 70,000 industrial chemicals in common use. In contrast, regulatory agencies have established fewer than 1000 exposure limits. Determination of an appropriate exposure limit is an exhaustive process; as an illustration, the U.S. Occupational Safety and Health Administration (OSHA) has promulgated fewer than 30 standards (new permissible exposure limits (PELs) for 16 agents, and standards without PELs for 13 carcinogens) since 1970. The European Union's REACH (Regulation on Registration, Evaluation, Authorization and Restriction of Chemicals) framework will require several decades to determine the exposure limits for common chemicals.

The assessment backlog is so critical that OSHA recommends that the employers consider using alternative occupational exposure limits established by the National Institute for Occupational Safety and Health (NIOSH) and American

Conference of Industrial Hygienists (ACGIH). Traditional toxicological testing is costly, time consuming, reliant on animal models, and fraught with uncertainty stemming from interspecies extrapolation. Tox21, an interagency project between the National Toxicology Program, the U.S. Environmental Protection Agency, the National Institutes of Health, and the Food and Drug Administration, is a high-throughput testing prototype robot created to address both the knowledge gap and problems of traditional toxicity testing. Tox21 will screen thousands of chemicals using advanced *in vitro* and cell-based assays and non-rodent models such as zebrafish in far less time than previously possible.

The evaluation of risk subsequent to exposure is an essential component of industrial toxicology. It is critical that readers remember that exposure only represents the *opportunity* for contact with a chemical. An exposure does not guarantee that an adverse effect will result. A dose is the amount of the chemical entering the body following an exposure. There are both harmful and safe doses of all chemicals. As Paracelsus said, "All things are poisons, for there is nothing without poisonous qualities . . . it is only the dose which makes a thing poison." Exposure and dose both need to be evaluated for an adequate hazard assessment. This edition of the text includes an assessment of risk where possible.

*Hamilton & Hardy's Industrial Toxicology* was prepared as a concise reference for academics and professionals alike. There is a wealth of information available on industrial exposures and toxicants. Distillation of these resources into something relevant can be daunting. It is our hope that this text will be that something relevant for our readers.

MARIE M. BOURGEOIS, PH.D.



# **SECTION I**

---

## **INTRODUCTION**

**SECTION EDITOR: RAYMOND D. HARBISON**



---

# 1

---

## THE MODERN APPROACH TO THE DIAGNOSIS OF OCCUPATIONAL DISEASE

RAYMOND D. HARBISON AND JEFFREY H. MANDEL

### BACKGROUND

An understanding of the health effects that may occur from occupational exposures is critical in terms of the potential human toll and an industry's success and sustainability. The diagnosis of workplace-induced diseases is necessary if the disease in question is to be prevented. In the context of modern medicine, the diagnosis of an occupational disease is a multidisciplinary process and includes input from professionals in occupational medicine, nursing, industrial hygiene, toxicology, epidemiology, engineering, and others. Though physicians are primarily responsible for making an individual diagnosis, the remaining disciplines are critical parts of the process for establishing the nature and cause of the disease(s). It is the collective group that has become paramount to the understanding and control of occupational disease within modern societies. The diagnosis of an occupational disease may be understood in the context of a public health model, which incorporates the interplay between the agent, the host, and the disease. With this approach, the agent may be physical, chemical, or biological and has the potential to cause harm depending on its characteristics (e.g., corrosive, pathogenic, and carcinogenic), the exposure concentration and duration, and the ability to target organs in exposed individuals. The host is the individual or population exposed to the agent. The disease results from the interaction of these two factors. The host in this model includes healthy individuals as well as susceptible individuals (e.g., genetic predisposition and life stage). With acute or chronic high-level exposures, host susceptibility generally increases, due to a variety of mechanisms, including saturation of detoxification reactions and increased bioactivation. Manufacturing

facilities control exposures through engineering controls, personal protective equipment, chemical substitution, area monitoring, personal monitoring, hazard communication, and employee training and education.

Despite the vast number of professionals involved, the diagnosis of an occupational disease is complicated by important factors. First, many diseases that occur as a result of workplace exposures (e.g., asthma from isocyanates) may also occur from non-workplace exposures to the same compounds or may be caused by other agents (nonspecificity). Second, disease manifestation is often idiopathic and may be attributed to the workplace purely on the basis of the disease postceding employment. Third, the majority of chemicals in commerce either have not been tested in experimental animals or have been tested but lack data on the mode of action and human relevance of adverse effects. The absence of this type of information complicates extrapolations from animal studies to workers. Finally, many tests used in clinical medicine are not specific for identifying exposures to an agent of interest. For example, a blood test that reveals high carboxyhemoglobin (COHb) levels only confirms an internal dose of carbon monoxide. It does not confirm whether the source exposure was to carbon monoxide, methylene chloride, or some other causative agent. Similarly, chest radiograph findings that suggest interstitial lung disease do not confirm exposures to a specific causative agent (e.g., wood dust). Testing of workers is subject to each test's sensitivity, specificity, and positive and negative predictive value. To complicate matters, many tests do not have established "gold standards" to which they may be compared. All of these issues may potentially compromise the accuracy of diagnoses.

As alluded to in the above examples, a multilevel assessment is needed in the diagnosis of an occupational disease. The exposure in question must be assessed in terms of what is known about it, whether the worker's complaints are consistent with this exposure, and insights into the actual work environment are the initial necessary perspectives needed. These are followed by a detailed account of the individual's illness, the person's medical history, occupational history, physical findings, laboratory findings, and a review of the epidemiological literature involving this person's exposure-disease relationship. Finally, some type of assessment of causation is necessary to determine whether there is adequate information to suggest that an exposure could produce the disease in question. This assessment typically involves a comprehensive review of the existing epidemiological literature on the topic. All this is theoretically needed before an occupational disease can be considered. Each of these will be considered in greater detail in the subsequent paragraphs.

## COMPONENTS OF THE DIAGNOSIS

### The History of Illness

The worker's disease history is often the only information available to the team of professionals assigned to determine the etiology of the disease. In some cases, associations with the workplace are based entirely upon this history, hence its importance. Accordingly, the trained interviewer attempts to have as much of this as possible iterated directly in the worker's own words. A description of the worker's symptoms is the basis of this history, but there needs to also be a focus on the occupational aspects of the illness. Identification of the illness occurring temporally with the workplace is helpful since exposure-disease associations may become worse during the workday, the workweek, often with improvement after work, or on weekends away from the job. It is also important to clarify the duration of the exposure and whether coworkers with similar jobs have had health problems. Since some illnesses have long latencies, the examiner must determine the prior work history of an individual. The practitioner may also use other sources of information, including the employer, incident reports, the state or federal Occupational Safety and Health Administration (OSHA), and an industrial hygienist familiar with the workplace controls, practices, and safety data sheets (SDS). The history should include the following:

1. *Occupational Factors.* Occupational factors must be assessed and understood. These include insights into the agent (exposure) in question as well as the involved work area. Part of this understanding is obtained through an evaluation of processes, engineering

controls, personal protective equipment, employee training and compliance, and the identification of potential causative agents (e.g., which materials or chemicals are used?) and opportunities for exposure. The chemicals used must be understood in terms of the potential routes of exposure (e.g., inhalation of volatile organics), toxicokinetics (i.e., absorption, distribution, metabolism, and elimination), and toxicity.

2. *Nonoccupational Factors.* Many diseases that may originate from exposures to a causative agent in the workplace may also occur outside of the workplace. Asthma, for example, may be triggered by occupational or consumer exposure to certain isocyanates, but it may also be triggered by exposure to cat dander. Lung cancer may be related to asbestos exposure, smoking, or both. Few diseases have only an occupational basis. In fact, estimates of 5–10% of all cancers have been attributed to exposures in the occupational setting (Doll, 1984). The vast majority of cancers are not associated with occupational exposures and are thought to be multifactorial in origin (e.g., environmental exposures, lifestyle choices/hobbies, and genetic predisposition). In particular, attention must be given to these factors in the assessment of occupational disease. Especially important are exposures that occur to individuals with preexisting diseases, since these may complicate an illness resulting from an exposure. For example, an individual with underlying chronic bronchitis may have a reduced capacity for pulmonary clearance, which may predispose this individual to an adverse outcome following exposure to specific types of agents (e.g., fibers or insoluble particles).

### The Physical and Laboratory Examinations

The physical and laboratory examinations are regarded as means of verifying what is already suspected following the history of illness. A skilled examiner is able to combine these two areas with a high likelihood of an accurate diagnosis, without any additional evaluation. The occupational physical examination, such as the history of illness, needs to focus on the organ where known toxicity occurs. If the worker has breathing difficulties and has exposure to a lung irritant, the examination will need to focus on the respiratory system. Other organ systems are evaluated for the sake of being thorough and to identify additional potential areas of abnormality.

Following the physical examination, the examiner may need to verify the disease suspected with the use of specific tests. In the above case, it would be appropriate to perform a pulmonary function test (e.g., spirometry) to evaluate the worker's inhalation and exhalation during normal breathing